Drug substitution and adjuvant therapy in patients with genetics related infertility: A review

Drug Discov Ther. 2023 May 15;17(2):73-86. doi: 10.5582/ddt.2022.01096. Epub 2023 Mar 30.

Abstract

With the in-depth study of the human genome and the increasing popularity of gene sequencing, it has been gradually confirmed that genetics can play a crucial role in infertility. To provide references for clinical treatment, we have focused on genes and drug therapy for genetic infertility. This review recommends adjuvant therapy and drug substitution. Examples of these therapies include antioxidants (such as folic acid, vitamin D, vitamin E, inositol, coenzyme Q10 etc.), metformin, anticoagulants, levothyroxine, dehydroepiandrosterone, glucocorticoids, and gonadotropins etc. Based on the pathogenesis, we provide an overview of the current knowledge, including randomized controlled trials and systematic reviews, and predict potential target genes and signaling pathways, proposing possible future strategies for the use of targeted drugs to treat infertility. Non-coding RNAs are anticipated to become a novel target for the treatment of reproductive illnesses since they have a significant role in controlling the occurrence and development of reproductive diseases.

Keywords: Genetics; adjuvant therapy; drug substitution; infertility; targeted drugs.

Publication types

  • Review

MeSH terms

  • Antioxidants / therapeutic use
  • Drug Substitution*
  • Folic Acid / therapeutic use
  • Humans
  • Infertility* / drug therapy
  • Inositol / therapeutic use

Substances

  • Folic Acid
  • Antioxidants
  • Inositol